# An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine

> **NCT00165880** · PHASE2 · TERMINATED · sponsor: **Eisai Limited** · enrollment: 62 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** E7070

## Key facts

- **NCT ID:** NCT00165880
- **Lead sponsor:** Eisai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** This study was stopped prematurely due to lack of efficacy.
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165880, "An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00165880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*